Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials.

Autor:	Batool S; Internal Medicine, Hameed Latif Hospital, Lahore, PAK., Vuthaluru K; Pediatrics, Jawaharlal Nehru Medical College, Belgaum, IND., Hassan A; Internal Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, PAK., Bseiso O; College of Medicine, Hebron University, Hebron, PSE., Tehseen Z; Internal Medicine, Allama Iqbal Medical College, Lahore, PAK., Pizzorno G; General Medicine, University of Carabobo, Orlando, USA., Rodriguez Reyes Y; Medicine, Universidad de Oriente, Núcleo Anzoategui, Barcelona, VEN., Saleem F; Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Jan 12; Vol. 15 (1), pp. e33676. Date of Electronic Publication: 2023 Jan 12 (Print Publication: 2023).
DOI:	10.7759/cureus.33676
Abstrakt:	This meta-analysis was conducted with the aim to assess the safety and efficacy of favipiravir in treating patients with coronavirus disease 2019 (COVID-19). It was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We performed a thorough search of online databases including PubMed, EMBASE, and the Cochrane Library from their inceptions to November 30, 2022, using the following search terms: "Favipiravir" AND "COVID-19". We included randomized control trials (RCTs) that were conducted to determine the efficacy and safety of favipiravir for COVID-19. Efficacy outcomes assessed in this meta-analysis included time to viral clearance in days, time to clinical improvement in days, need for supplementary oxygen, and requirement of ICU admission. For safety outcomes, we compared overall adverse events and serious adverse events that had occurred during the treatment between the patients in the treatment group and the control group. Eight studies involving 1,448 patients were included in this meta-analysis. The results showed that no significant differences were found between the two groups in terms of time to viral clearance, time to clinical improvement, and the need for supplementary oxygen and ICU admission. In terms of safety, no significant differences were found between the two groups in relation to adverse events and serious adverse events. The current study found that favipiravir did not exert any beneficial impact on reducing ICU admission, the need for oxygen therapy, and time to viral clearance. However, a slight benefit was reported with regard to the time for clinical improvement, but it was insignificant between the two study groups. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Batool et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu